14 Best Biotech Stocks to Buy Right Now

Page 2 of 14

13. BeOne Medicines Ltd. (NASDAQ:ONC)

Number of Hedge Fund Holders: 28

BeOne Medicines Ltd. (NASDAQ:ONC) ranks among the best biotech stocks to buy. On September 18, Barclays began coverage of BeOne Medicines Ltd. (NASDAQ:ONC), rating it Overweight and setting a price target of $385 on the company’s shares. The firm cited two anticipated “value-inflecting pivotal data readouts” that might propel the oncology company’s growth.

The first projected catalyst is data on BeOne’s BTK inhibitor in first-line mantle cell lymphoma, which is due in the latter half of 2025. Barclays also mentioned that data in first-line gastroesophageal cancer for the company’s PD1 inhibitor with anti-HER2 mixture will come in the fourth quarter of 2025.

Another significant driver for BeOne Medicines Ltd. (NASDAQ:ONC), according to Barclays, is the significance of topline pivotal data for zanidatamab, with or without tislelizumab, in first-line gastroesophageal adenocarcinoma.

BeOne Medicines Ltd. (NASDAQ:ONC) is a global biotechnology company that specializes in oncology medicines, particularly for blood cancers and solid tumors.

Page 2 of 14